Arcoma AB

OM:ARCOMA Rapport sur les actions

Capitalisation boursière : SEK 203.7m

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Arcoma Croissance future

Future contrôle des critères 4/6

Arcoma devrait augmenter ses bénéfices et son chiffre d'affaires de 16.1% et de 8% par an respectivement. Le BPA devrait croître de de 14.4% par an. Le rendement des capitaux propres devrait être 21.8% dans 3 ans.

Informations clés

16.1%

Taux de croissance des bénéfices

14.4%

Taux de croissance du BPA

Medical Equipment croissance des bénéfices25.5%
Taux de croissance des recettes8.0%
Rendement futur des capitaux propres21.8%
Couverture par les analystes

Low

Dernière mise à jour16 Aug 2024

Mises à jour récentes de la croissance future

Recent updates

At kr15.20, Is Arcoma AB (STO:ARCOMA) Worth Looking At Closely?

Aug 07
At kr15.20, Is Arcoma AB (STO:ARCOMA) Worth Looking At Closely?

Is Now The Time To Look At Buying Arcoma AB (STO:ARCOMA)?

Apr 26
Is Now The Time To Look At Buying Arcoma AB (STO:ARCOMA)?

Arcoma AB's (STO:ARCOMA) P/E Is Still On The Mark Following 25% Share Price Bounce

Feb 06
Arcoma AB's (STO:ARCOMA) P/E Is Still On The Mark Following 25% Share Price Bounce

Is Arcoma (STO:ARCOMA) A Risky Investment?

Jan 15
Is Arcoma (STO:ARCOMA) A Risky Investment?

We Think Arcoma (STO:ARCOMA) Is Taking Some Risk With Its Debt

Sep 11
We Think Arcoma (STO:ARCOMA) Is Taking Some Risk With Its Debt

Is Arcoma (STO:ARCOMA) Using Too Much Debt?

Jun 08
Is Arcoma (STO:ARCOMA) Using Too Much Debt?

Is Arcoma AB (STO:ARCOMA) Potentially Undervalued?

Apr 27
Is Arcoma AB (STO:ARCOMA) Potentially Undervalued?

Does Arcoma (STO:ARCOMA) Have A Healthy Balance Sheet?

Dec 22
Does Arcoma (STO:ARCOMA) Have A Healthy Balance Sheet?

Is Arcoma (STO:ARCOMA) Using Too Much Debt?

May 03
Is Arcoma (STO:ARCOMA) Using Too Much Debt?

These 4 Measures Indicate That Arcoma (STO:ARCOMA) Is Using Debt Extensively

Oct 28
These 4 Measures Indicate That Arcoma (STO:ARCOMA) Is Using Debt Extensively

Is Arcoma (STO:ARCOMA) A Risky Investment?

Mar 17
Is Arcoma (STO:ARCOMA) A Risky Investment?

Is Arcoma AB (STO:ARCOMA) Potentially Undervalued?

Feb 04
Is Arcoma AB (STO:ARCOMA) Potentially Undervalued?

Have Insiders Sold Arcoma AB (STO:ARCOMA) Shares Recently?

Jan 14
Have Insiders Sold Arcoma AB (STO:ARCOMA) Shares Recently?

Arcoma AB's (STO:ARCOMA) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Jan 12
Arcoma AB's (STO:ARCOMA) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

These 4 Measures Indicate That Arcoma (STO:ARCOMA) Is Using Debt Reasonably Well

Dec 17
These 4 Measures Indicate That Arcoma (STO:ARCOMA) Is Using Debt Reasonably Well

Estimating The Fair Value Of Arcoma AB (STO:ARCOMA)

Nov 21
Estimating The Fair Value Of Arcoma AB (STO:ARCOMA)

Prévisions de croissance des bénéfices et des revenus

OM:ARCOMA - Estimations futures des analystes et données financières antérieures (SEK Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/20262141918231
12/31/20252001613181
12/31/2024183143101
6/30/2024176131922N/A
3/31/202417291921N/A
12/31/202316331719N/A
9/30/20231530-13N/A
6/30/20231460-23N/A
3/31/2023138128N/A
12/31/20221252-40N/A
9/30/2022105-658N/A
6/30/202299-1002N/A
3/31/2022105-11-11-8N/A
12/31/2021117-7-6-2N/A
9/30/2021126-6-10-7N/A
6/30/2021125-2-7-2N/A
3/31/2021121-1-60N/A
12/31/20201171-57N/A
9/30/20201228-142N/A
6/30/202013010320N/A
3/31/202013210218N/A
12/31/20191347011N/A
9/30/20191335511N/A
6/30/20191322-32N/A
3/31/2019129114N/A
12/31/2018119-2-10N/A
9/30/2018111-1-3-1N/A
6/30/201898-6-13-11N/A
3/31/201894-10N/A-8N/A
12/31/201792-10N/A-9N/A
9/30/201798-9N/A0N/A
6/30/2017108-4N/A3N/A
3/31/2017106-5N/A0N/A
12/31/2016102-12N/A-5N/A
9/30/2016106-12N/A-12N/A
6/30/2016105-13N/A-9N/A
3/31/2016104-15N/A-17N/A
12/31/2015123-6N/A-5N/A
9/30/2015117-6N/A-4N/A
6/30/2015119-5N/A-2N/A
3/31/20151331N/A5N/A
12/31/20141301N/A-1N/A
9/30/2014134-7N/A-1N/A
12/31/2013108-14N/A-12N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de ARCOMA ( 16.1% par an) est supérieure au taux d'épargne ( 1.1% ).

Bénéfices vs marché: Les bénéfices de ARCOMA ( 16.1% par an) devraient croître plus rapidement que le marché Swedish ( 15.8% par an).

Croissance élevée des bénéfices: Les bénéfices de ARCOMA devraient augmenter, mais pas de manière significative.

Chiffre d'affaires vs marché: ARCOMA's revenue (8% per year) is forecast to grow faster than the Swedish market (1% per year).

Croissance élevée des revenus: ARCOMA's revenue (8% per year) is forecast to grow slower than 20% per year.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: ARCOMA's Return on Equity is forecast to be high in 3 years time (21.8%)

Découvrir les entreprises en croissance

7D

1Y

7D

1Y

7D

1Y